Clinical characteristics of 53 patients with classical Hodgkin lymphoma analyzed by the use of array comparative genomic hybridization
| . | All patients . | Treatment success . | Treatment failure . | P . |
|---|---|---|---|---|
| n (%) | 53 | 30 (57) | 23 (43) | |
| Median age, y (range) | 36 | 36 (15-74) | 29 (12-71) | .559 |
| Male sex, % | 66 | 56 | 78 | .100 |
| Histology, % | .831 | |||
| Nodular sclerosis | 82 | 87 | 78 | |
| Mixed cellularity | 8 | 7 | 9 | |
| Lymphocyte rich | 4 | 2 | 4 | |
| Lymphocyte depleted | 0 | 0 | 0 | |
| NOS | 6 | 2 | 9 | |
| Advanced stage, % | 62 | 40 | 91 | < .001* |
| B symptoms, % | 30 | 20 | 43 | .065 |
| IPS 4 or more, high-risk | 17 | 13 | 22 | .419 |
| Mass size, median (range) in cm | 5 | 4 | 6 | .210 |
| 10 or more cm, % | 25 | 23 | 26 | 1.000 |
| Treatment | .249 | |||
| ABVD type ± radiation, % | 94 | 90 | 100 | |
| Extended-field radiation alone, % | 6 | 10 | 0 |
| . | All patients . | Treatment success . | Treatment failure . | P . |
|---|---|---|---|---|
| n (%) | 53 | 30 (57) | 23 (43) | |
| Median age, y (range) | 36 | 36 (15-74) | 29 (12-71) | .559 |
| Male sex, % | 66 | 56 | 78 | .100 |
| Histology, % | .831 | |||
| Nodular sclerosis | 82 | 87 | 78 | |
| Mixed cellularity | 8 | 7 | 9 | |
| Lymphocyte rich | 4 | 2 | 4 | |
| Lymphocyte depleted | 0 | 0 | 0 | |
| NOS | 6 | 2 | 9 | |
| Advanced stage, % | 62 | 40 | 91 | < .001* |
| B symptoms, % | 30 | 20 | 43 | .065 |
| IPS 4 or more, high-risk | 17 | 13 | 22 | .419 |
| Mass size, median (range) in cm | 5 | 4 | 6 | .210 |
| 10 or more cm, % | 25 | 23 | 26 | 1.000 |
| Treatment | .249 | |||
| ABVD type ± radiation, % | 94 | 90 | 100 | |
| Extended-field radiation alone, % | 6 | 10 | 0 |
ABVD indicates doxorubicin, bleomycin, vinblastine, and dacarbazine; IPS, International Prognostic Scoring; and NOS, not otherwise specified.
Statistically significant.